产品
编 号：F395406
分子式：C170H254N44O40
分子量：3554.11
分子式：C170H254N44O40
分子量：3554.11
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 577782-52-6
产品详情
生物活性：
CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog. CTCE-0214 shows anti-inflammatory activity, and can be used in inflammation sepsis and systemic inflammatory syndromes research.
体内研究：
CTCE-0214 (intravenous injection; 1-25 mg/kg; once) treatment inhibits Lipopolysaccharide-induced plasma TNF-α production.CTCE-0214 (intraperitoneal injection and intravenous injection; 25 mg/kg; once) decreases Zymosan-induced plasma TNF-α production.Animal Model:Male CD-1 mice injected with Lipopolysaccharide
Dosage:1, 10, or 25 mg/kg
Administration:Intravenous injection; 1, 10, or 25 mg/kg; once
Result:Decreased LPS-induced plasma TNF-α production in a dose dependent manor with a 93% reduction.Showed no significant effect on LPS-induced plasma IL-6 and IL-10 production.
Animal Model:Zymosan-induced peritonitis mice model
Dosage:25 mg/kg
Administration:Intraperitoneal injection and intravenous injection; 25 mg/kg; once
Result:Showed a significant reduction in plasma TNF-α (53 reduction, p<0.05).
体外研究：
CTCE-0214 (0.01-0.1 ng/mL; 4 d) increases the expansion of CD34+ cells subsets.
CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog. CTCE-0214 shows anti-inflammatory activity, and can be used in inflammation sepsis and systemic inflammatory syndromes research.
体内研究：
CTCE-0214 (intravenous injection; 1-25 mg/kg; once) treatment inhibits Lipopolysaccharide-induced plasma TNF-α production.CTCE-0214 (intraperitoneal injection and intravenous injection; 25 mg/kg; once) decreases Zymosan-induced plasma TNF-α production.Animal Model:Male CD-1 mice injected with Lipopolysaccharide
Dosage:1, 10, or 25 mg/kg
Administration:Intravenous injection; 1, 10, or 25 mg/kg; once
Result:Decreased LPS-induced plasma TNF-α production in a dose dependent manor with a 93% reduction.Showed no significant effect on LPS-induced plasma IL-6 and IL-10 production.
Animal Model:Zymosan-induced peritonitis mice model
Dosage:25 mg/kg
Administration:Intraperitoneal injection and intravenous injection; 25 mg/kg; once
Result:Showed a significant reduction in plasma TNF-α (53 reduction, p<0.05).
体外研究：
CTCE-0214 (0.01-0.1 ng/mL; 4 d) increases the expansion of CD34+ cells subsets.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备